Intravenous thrombolysis and platelet count
Authors:
- Henrik GensickeHGHenrik Gensicke
- Abdulaziz S. Al SultanASAbdulaziz S. Al Sultan
- Daniel StrbianDSDaniel Strbian
- Christian HametnerCHChristian Hametner
- Sanne M. ZinkstokSZSanne M. Zinkstok
- Solène MoulinSMSolène Moulin
- Olivier BillOBOlivier Bill
- Andrea ZiniAZAndrea Zini
- Visnja PadjenVPVisnja Padjen
- Georg KägiGKGeorg Kägi
- Alessandro PezziniAPAlessandro Pezzini
- David J. SeiffgeDSDavid J. Seiffge
- 20 February 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 90 (8) , e690-e697
Abstract
Objective To study the effect of platelet count (PC) on bleeding risk and outcome in stroke patients treated with IV thrombolysis (IVT) and to explore whether withholding IVT in PC < 100 × 109/L is supported. Methods In this prospective multicenter, IVT register–based study, we compared PC with symptomatic intracranial hemorrhage (sICH; Second European-Australasian Acute Stroke Study [ECASS II] criteria), poor outcome (modified Rankin Scale score 3–6), and mortality at 3 months. PC was used as a continuous and categorical variable distinguishing thrombocytopenia (450 × 109/L), and normal PC (150–450 × 109/L [reference group]). Moreover, PC < 100 × 109/L was compared to PC ≥ 100 × 109/L. Unadjusted and adjusted odds ratios (ORs) with 95% confidence intervals (CIs) from the logistic regression models were calculated. Results Among 7,533 IVT-treated stroke patients, 6,830 (90.7%) had normal PC, 595 (7.9%) had thrombocytopenia, and 108 (1.4%) had thrombocytosis. Decreasing PC (every 10 × 109/L) was associated with increasing risk of sICH (ORadjusted 1.03, 95% CI 1.02–1.05) but decreasing risk of poor outcome (ORadjusted 0.99, 95% CI 0.98–0.99) and mortality (ORadjusted 0.98, 95% CI 0.98–0.99). The risk of sICH was higher in patients with thrombocytopenic than in patients with normal PC (ORadjusted 1.73, 95% CI 1.24–2.43). However, the risk of poor outcome (ORadjusted 0.89, 95% CI 0.39–1.97) and mortality (ORadjusted 1.09, 95% CI 0.83–1.44) did not differ significantly. Thrombocytosis was associated with mortality (ORadjusted 2.02, 95% CI 1.21–3.37). Forty-four (0.3%) patients had PC < 100 × 109/L. Their risks of sICH (ORunadjusted 1.56, 95% CI 0.48–5.07), poor outcome (ORadjusted 1.63, 95% CI 0.82–3.24), and mortality (ORadjusted 1.38, 95% CI 0.64–2.98) did not differ significantly from those of patients with PC ≥ 100 × 109/L. Conclusion Lower PC was associated with increased risk of sICH, while higher PC indicated increased mortality. Our data suggest that PC modifies outcome and complications in individual patients, while withholding IVT in all patients with PC < 100 × 109/L is challenged.Keywords
This publication has 30 references indexed in Scilit:
- Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic StrokeStroke, 2016
- Intravenous Thrombolysis in Patients Dependent on the Daily Help of Others Before StrokeStroke, 2016
- Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trialsThe Lancet, 2014
- Waiting for Platelet Counts Causes Unsubstantiated Delay of Thrombolysis TherapyEuropean Neurology, 2013
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Thrombolysis in Stroke Despite Contraindications or Warnings?Stroke, 2013
- IV thrombolysis and statinsNeurology, 2011
- Unsuspected coagulopathy rarely prevents IV thrombolysis in acute ischemic strokeNeurology, 2009
- Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008Cerebrovascular Diseases, 2008
- Usefulness of Checking Platelet Count Before Thrombolysis in Acute Ischemic StrokeStroke, 2007